Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the cohorts

From: Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study

  All subjects n = 97 Normal mucosa (Marsh stage 0) n = 39 Lymphocytic enteritis (Marsh stage 1) n = 58 P
Demographic characteristics     
Females, n (%) 86 (89) 34 (87) 52 (90) 0.959
Age in years, mean (SD) 50 (8) 49 (7) 51 (9) 0.222
BMI, kg/m2, mean (SD) 26 (4) 25 (3) 28 (5) <0.001
Education level     
None, n (%) 2 (2) 0 2 (3) 0.658
Primary education, n (%) 71 (73) 29 (74) 42 (72) 0.983
Secondary education, n (%) 22 (23) 10 (26) 12 (21) 0.746
Higher education, n (%) 3 (3) 0 2 (3) 0.658
Employment status     
Employed, n (%) 45 (46) 21 (54) 24 (41) 0.317
Unemployed, n (%) 20 (21) 7 (18) 13 (22) 0.782
Homemaker, n (%) 17 (17) 8 (20) 9 (15) 0.717
Retired/pensioner, n (%) 15 (15) 3 (8) 12 (21) 0.147
First-degree relatives with CD/FMS     
Subjects with CD relatives, n (%) 10 (10) 0 10 (17) 0.016
Subjects with FMS relatives, n (%) 4 (4) 0 4 (7) 0.248
Gastroduodenal histopathological details     
IELs, mean (SD) 18 (3) 14 (2) 35 (5) <0.001
Helicobacter pylori (+), n (%) 41 (42) 17 (43) 24 (41) 0.426
HLA haplotype     
HLA-DQ2 A1/B1, n (%) 46 (47) 15 (38) 31 (53) 0.214
HLA-DQ2 (-), n (%) 15 (15) 4 (10) 11 (19) 0.381
Serum autoantibodies     
Anti tTG-2, U/ml, mean (SD) 0.7 (0.6) 0.5 (0.1) 0.9 (0.7) <0.001
RF, IU/m, mean (SD) 12.8 (1.7) 12.6 (0.9) 12.9 (2.1) 0.552
Anti-TPO (+), U/ml, mean (SD) 30 (111) 20 (30) 51 (140) 0.115
ANAs (+), n (%) 26 (27) 3 (8) 23 (40) 0.001
AMAS (+), n (%) 4 (4) 0 4 (7) 0.248
  1. Data are expressed as frequency (n) and percentage of the total value (%), or mean and standard deviation (SD). BMI, body mass index; IELs, intraepithelial lymphocyte count from 100 epithelial cells; anti-tTG-2, anti-tissue transglutaminase-2 antibodies; RF, rheumatoid factor; HLA-DQ2, major histocompatibility complex class II; anti-TPO, anti-thyroid peroxidase antibodies; ANAs, anti-nuclear antibodies; AMAs, anti-mitochondrial antibodies.